Pharma Industry Current News Summary (Feb 24, 2021) | Answers

Takeda Nova Bucks’ new corona vaccine begins national P1 / 2 trial

Takeda Pharmaceutical Company Limited announced on February 24 that it had begun phase 1/2 (P1 / 2) clinical trials in Japan for the new coronavirus vaccine developed by Novabax. Takeda will build a system to produce more than 250 million doses of the recombinant Novabax vaccine annually, and will be responsible for national development and supply. Try to start supplying later this year.

MSD launches 9-valent HPV vaccine “Silgard”

MSD announced on February 24 that it had released the 9-valent HPV vaccine “Silgard 9 Aqueous Suspension Intramuscular Syringe.” In addition to the 4 types (6, 11, 16, 18 types) covered by the conventional 4-valent HPV vaccine “Gardasil”, 5 types (31, 33, 45, 52, 58) are covered. It prevents cervical cancer and its precursor lesions, vulvar intraepithelial neoplasia 1/2/3, vaginal intraepithelial neoplasia 1/2/3 and the condyloma acuminata caused by these.

Improve the efficiency of clinical trials with the Nippon Chemiphar blockchain and materialize studies with Sasumedo

Nippon Chemiphar announced on February 24 that it had begun concrete studies to improve the efficiency of clinical trials using Sasumedo and blockchain technology. The two companies signed a business and capital alliance in August last year, and this initiative is part of that. With the Sasumedo system, our goal is to improve monitoring efficiency while maintaining the accuracy and reliability of the data.

Additional approved indication for urothelial cancer “Babento”

On February 24, Merck Biopharma announced the immune checkpoint inhibitor anti-PD-L1 antibody “Babento” (chemical name: avelumab) in “Maintenance therapy after chemotherapy for unresectable urothelial cancer”, and announced that it obtained approval for additional indications. In a P3 study of patients who did not progress with first-line platinum-containing treatment, overall survival was significantly longer than in the control group. This is the only immune checkpoint inhibitor that has been approved for maintenance therapy for urothelial cancer.

Sasumedo jointly develops an application for the treatment of CKD with the University of Tohoku

Sasmed announced on February 24 that joint development of a therapeutic application for patients with chronic kidney disease (CKD) had begun with the Department of Internal Disability Studies, Tohoku University School of Medicine. Renal rehabilitation is effective for CKD patients, but the shortage of medical staff is a problem and there is a limit to implementation in individual medical institutions. The Japan Renal Rehabilitation Society will also cooperate in the development of therapeutic applications.

Employees sent to Shionogi Health Center to support crown-related work

Shionogi Pharmaceutical Co., Ltd. announced on February 22 that it will dispatch company employees and group companies to public health centers in Osaka and Tokyo. We support operations related to the novel coronavirus, such as entering information on patient outbreaks and preparing and submitting test request documents. The deadline is until March 31 and between 20 and 30 people will be sent.

Answers News Editorial Department Reports on Pharmaceutical Companies
・ Takeda Pharmaceutical Company Limited
・ Shionogi Pharmaceutical

→ See other companies